Rapp.O
RAPP.O is a pharmaceutical company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.
Business. RAPP.O is a pharmaceutical company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.
Analyst recommendations
13 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
RAPP.O is a pharmaceutical company operating within the Health Care sector, though specific business activities and revenue generation mechanisms are not detailed in the available data.
The company maintains a conservative capital structure with zero debt-to-equity ratio and total liabilities of $27.8 million against total assets of $512.4 million. Total equity stands at $484.7 million, providing a substantial buffer. However, liquidity is assessed as low, supported by cash and equivalents of $52.6 million, which may be insufficient given the negative operating cash flow of $87.5 million. The price-to-book ratio is 4.34, indicating the market values the company significantly above its tangible book value despite current unprofitability.
Profitability metrics are negative, with a return on equity of -23% and return on assets of -21.76%. The company reported an operating income of -$125.1 million and net income of -$111.5 million, reflecting significant pre-commercial or development-stage losses. The EV/EBITDA ratio is negative at -16.38, consistent with companies that have not yet achieved positive earnings before interest, taxes, depreciation, and amortization.
Segment and geographic revenue data are not available in the provided input, preventing an analysis of revenue concentration or regional exposure. The absence of this data limits the ability to assess diversification risks or specific market dependencies.
Growth trajectory cannot be determined from the available data as historical revenue and net income trends for the past five years or eight quarters are not provided. The current financial snapshot shows a single period of significant net loss, but without historical context, the direction of growth or decline is unclear.
Risk assessment indicates low liquidity risk and low dilution risk, with no immediate filing-based flags detected. The primary risk appears to be operational, stemming from the negative cash flow and lack of profitability. The low dilution risk suggests that the company is not currently issuing significant new shares, which is positive for existing shareholders.
Recent observations include analyst estimates with a mean price target of $56.73 and a median of $56.00, indicating a potential upside from the current market price of $44.00. The mean recommendation is 1.54, with 6 strong buys and 7 buys, suggesting strong analyst confidence in the company's future prospects despite current financial losses. No specific news events or filing observations were detailed beyond the reconciler enqueue triggers.
- The company has a strong balance sheet with zero debt and $484.7 million in equity, but faces liquidity challenges due to negative operating cash flow of $87.5 million.
- Profitability is negative with ROE of -23% and net income of -$111.5 million, typical for pre-commercial pharmaceutical firms.
- Analyst sentiment is strongly positive with a mean recommendation of 1.54 and a mean price target of $56.73, implying significant upside from the current $44.00 price.
- Dilution risk is assessed as low, with no immediate flags for share issuance.
- Lack of segment, geographic, and historical trend data limits the depth of fundamental analysis.
Bull / Bear case
analysis pipelineIn focus — financials by report
Revenue $20.0M; Operating income +10,7% YoY.
- ▍Revenue $20.0M
- ▍Operating income +10,7% YoY
- ▍Net income +17,5% YoY
- ▍Free cash flow +18,2% YoY
- ▍Net margin -99.3%
Operating income −63,7% YoY; Net income −69,0% YoY.
- ▍Operating income −63,7% YoY
- ▍Net income −69,0% YoY
- ▍Free cash flow −68,8% YoY
Operating income −38,6% YoY; Net income −53,5% YoY.
- ▍Operating income −38,6% YoY
- ▍Net income −53,5% YoY
- ▍Free cash flow −53,3% YoY
Operating income −41,8% YoY; Net income −47,5% YoY.
- ▍Operating income −41,8% YoY
- ▍Net income −47,5% YoY
- ▍Free cash flow −40,1% YoY
Operating income -$27.1M.
- ▍Operating income -$27.1M
Operating income -$23.5M.
- ▍Operating income -$23.5M
Operating income -$21.6M.
- ▍Operating income -$21.6M
Operating income -$20.8M.
- ▍Operating income -$20.8M
Operating income −50,6% YoY; Net income −42,4% YoY.
- ▍Operating income −50,6% YoY
- ▍Net income −42,4% YoY
- ▍Free cash flow −39,1% YoY
Operating income −129,6% YoY; Net income −125,1% YoY.
- ▍Operating income −129,6% YoY
- ▍Net income −125,1% YoY
- ▍Free cash flow −120,0% YoY
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -3,42 |
| Revenue | —no estimate | —no estimate | 20,0M USD |
| Operating income | —no estimate | —no estimate | -174,8M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Director · Stock Option (Right to Buy) → Common StockAcquired 15 200 @ $35,21grant · 2026-06-10
- Chief Scientific Officer · Stock Options (Right to Buy) → Common StockDisposed 6 000 @ $1,80exercise · 2026-02-19
- Chief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 130 000 @ $27,75grant · 2026-02-02
- Chief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 103 000 @ $27,75grant · 2026-02-02
- Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 428 000 @ $27,75grant · 2026-02-02
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 148 000 @ $27,75grant · 2026-02-02
- Chief Development Officer · Stock Option (Right to Buy) → Common StockAcquired 120 000 @ $27,75grant · 2026-02-02
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Rapport Therapeutics, Inc. Market data — financials · 2026-07-31
- reconciler_enqueue (reconciler) on RAPP.O · 2026-07-31
- Rapport Therapeutics Inc Market data — analyst estimates · 2026-07-31
- Rapport Therapeutics Inc Market data — ESG · 2026-07-31
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,02 %$97M
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,01 %$92M
- Institutional Investor · as of 2026-03-310,01 %$224M
- Investment Managers · as of 2026-03-310,01 %$22M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$23M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$5M
- Funds · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$24M
- Investment Managers · as of 2025-12-310,00 %$55M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- Abraham N CeesayPresident, Chief Executive Officer, Director
Insider activity
- Director, Chief Executive Officer · Common StockSold 2 203 @ $42,11$93K · 2026-07-27
- Director, Chief Executive Officer · Common StockSold 7 @ $42,73$299 · 2026-07-27
- Director, Chief Executive Officer · Common StockSold 2 729 @ $40,57$111K · 2026-07-14
- Director, Chief Executive Officer · Common StockSold 5 481 @ $39,72$218K · 2026-07-14
- Chief Operating Officer · Common StockSold 3 792 @ $41,39$157K · 2026-06-30
- Chief Operating Officer · Common StockSold 1 000 @ $43,15$43K · 2026-06-30
- Chief Operating Officer · Common StockSold 3 308 @ $42,17$140K · 2026-06-30
- Chief Operating Officer · Common StockSold 1 900 @ $40,09$76K · 2026-06-30
- Director, Chief Executive Officer · Common StockSold 7 344 @ $39,77$292K · 2026-06-29
- Director, Chief Executive Officer · Common StockSold 876 @ $40,34$35K · 2026-06-29
- 10% owner · Common StockSold 18 572 @ $40,05$744K · 2026-05-26
- 10% owner · Common StockSold 133 618 @ $40,24$5,4M · 2026-05-11
- 10% owner · Common StockSold 5 018 @ $40,31$202K · 2026-05-08
- 10% owner · Common StockSold 271 495 @ $40,12$10,9M · 2026-05-07
- 10% owner · Common StockSold 426 005 @ $40,32$17,2M · 2026-04-17
- Chief Development Officer · Common StockSold 20 225 @ $39,99$809K · 2026-04-17
- Chief Development Officer · Common StockSold 10 200 @ $35,08$358K · 2026-04-14
- Chief Development Officer · Common StockSold 9 165 @ $34,97$321K · 2026-04-13
- Chief Development Officer · Common StockSold 500 @ $34,98$17K · 2026-04-10
- Chief Development Officer · Common StockSold 360 @ $34,90$13K · 2026-04-08
- Chief Operating Officer · Common StockSold 2 839 @ $28,55$81K · 2026-03-30
- Chief Operating Officer · Common StockSold 7 161 @ $28,04$201K · 2026-03-30
- Chief Development Officer · Common StockSold 10 115 @ $29,99$303K · 2026-03-25
- Chief Operating Officer · Common StockSold 2 014 @ $28,93$58K · 2026-03-05
- Chief Scientific Officer · Common StockOther 6 000 @ $1,80$11K · 2026-02-19
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 192.2%Derived (calculated)
- Return on equity (FY 2025-12-31): -23.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -21.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 26.17xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.06xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -74.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -7.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 24.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 24.3%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -42.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -34.9%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -50.6%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 55.6%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 58.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 62.7%Derived (calculated)
- Shares outstanding (annual): 47.77MSEC XBRL filing
- Total operating expenses (annual): USD 125.1MSEC XBRL filing
- Operating cash flow (annual): USD -87.47MSEC XBRL filing
- Total assets (annual): USD 512.43MSEC XBRL filing
- Operating income (annual): USD -125.1MSEC XBRL filing
- R&D expense (annual): USD 94.79MSEC XBRL filing
- Net income (annual): USD -111.48MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -3SEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -3SEC XBRL filing